Sermorelin is an artificial peptide derived from the growth hormone-releasing hormone (GHRH). Like GHRH, sermorelin acts on the pituitary gland by binding to somatotrophic cells and stimulating production of growth hormone. It was previously approved by the United States Food and Drug Administration for treating short stature problems; research has demonstrated its safety and effectiveness in increasing catch-up growth among undersized children by increasing GH levels and insulin-like growth factors 1 (IGF-1).
Human studies have demonstrated that sermorelin peptides can effectively increase GH levels and IGF-1 in healthy adults, leading to weight loss and increased body mass. Sermorelin and its related GH-releasing peptides are of particular interest due to their potential anti-aging benefits related to an increase in GH, such as improved body composition, more supple skin, improved well-being and increased libido.
What is Sermorelin?
Sermorelin was previously known as GHRH(1-29). This 29 amino acid peptide derives from an endogenous hormone known as growing hormone-releasing hormone (GHRH). Sermorelin belongs to a class of compounds known as GHRH secretagogues (GHSs), which are defined by their capacity to increase natural growth hormone production (GH).
What Does Sermorelin Do?
Sermorelin peptides for sale have been proven to be a safe compound through clinical trials conducted both on adults and children alike, with only minor irritation reported at the injection site.
Contrary to GH administration which causes an unnatural single bolus of hormone, sermorelin causes stimulation of endogenous GH secretion that mimics endogenous patterns. This is believed to be why sustained release of GH over 24 hours is necessary for optimal benefit from IGF-1-GH the axis.
Diagnosing Growth Hormone Deficiency
Numerous studies have demonstrated the utility of sermorelin in diagnosing growth hormone deficiencies (GHD), leading to its FDA approval in 1990. Sermorelin’s potency and rapid induction of growth hormone secretion when administered to subjects with an intact hypothalamic-pituitary axis (HPA) allows clinicians to pinpoint where a deficiency originated.
Treatment of Short Stature in Children
Sermorelin recently received FDA approval to treat children with small stature. Studies demonstrated that it can cause catch-up growth in up to 74% of these growth hormone deficient kids after 6 months of treatment, when administered daily via subcutaneous injection at 30 mg/kg before bed. Overall, Sermorelin proved well tolerated among this group when administered daily via subcutaneous injection before bed.
Increased Growth Hormone Secretion in Healthy Adults
A 1985 study which tested various analogs of GHRH found that intravenous (IV) application of sermorelin (referred to as GHRH(1-29)-NH2) can induce an increase in growth hormone levels and has similar efficacy as endogenous GHRH. Furthermore, sermorelin was well tolerated and did not impact concentrations of other hormones controlled by the pituitary gland. Subsequent studies have confirmed this effect even among older individuals with lower amounts of growth hormone production.
Enhancement in Cognitive Function
Sermorelin has been scientifically proven to enhance cognitive function due to the upregulation of IGF-1. After six months of regular treatment with sermorelin, elderly adults showed statistically significant improvements in various indicators of intelligence. Studies that followed up using other GHRH analogs also produced similar outcomes, providing further evidence about how GH-IGF-1 may play a role in age-related illnesses such as Alzheimer’s disease.
Sermorelin: Safety and Side Effects
Sermorelin has been proven to be a safe compound through clinical trials conducted both on adults and children alike, with only minor irritation reported at the injection site. This high safety profile can be attributed to its built-in safety circuitry which helps keep GH and IGF-1 levels within normal limits.
Sermorelin recognizes the exact sequence of 29 amino acids in natural GHRH and can bind on to its receptor in the anterior pituitary gland, leading to release of growth hormone. Thus, natural secretory pathways and associated regulatory mechanisms work together to maintain consistent levels of GH secretion.
Negative feedback inhibition applies to GH levels, meaning they are slowed down when they exceed a threshold. This natural mechanism also ensures IGF-1 stays within its normal limit – an essential regulation mechanism since excessive IGF-1 can have several undesirable side effects when using rhGH therapy.